Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Management

Noveris Announces Resignation Of CEO

By The Northwire Desk — AI Analysis Mar 10, 2026 · 16:05 NVRS · 0.33 Noveris Health Sciences Inc.
NVRS · Price

Executive Summary

  • Joshua Bartch resigned as director, president, and chief executive officer of Noveris Health Sciences Inc.
  • Jason Birmingham, previously chief strategy officer since February 2 2026, was appointed to assume the roles of director, president, and CEO.
  • The company issued a statement thanking Mr. Bartch for his service and wishing him well.

Key Details

  • Resignation effective as of the announcement date (March 10 2026).
  • Appointment of Jason Birmingham to all three positions previously held by Mr. Bartch.
  • Jason Birmingham’s prior role: Chief Strategy Officer, appointed on February 2 2026.
  • Contact information for the new CEO provided: email [email protected] and phone (888) 871‑3936.

Notable Quotes

(No direct quotes were included in the release.)

Read the original news release →

More from Noveris Health Sciences Inc.

Jun 05, 2026 · 16:20

Noveris Health Sciences Re-Engages R&D Partner on Psilocybin Pipeline Amid Stem Cell Pivot and Insider Sell-Off

M&A / Property May 21, 2026 · 14:12

Founder cashes out completely after boardroom shake‑up, casting a dark shadow over the sudden stem‑cell pivot.

Other Apr 29, 2026 · 12:05

Noveris Health Sciences Inc.

M&A / Property Apr 20, 2026 · 17:25

Noveris Health Sciences Inc.

Regulatory Mar 18, 2026 · 20:20

Noveris Announces Closing of Life Offering

Financings Mar 11, 2026 · 22:58

Noveris Announces Life Offering

Financings